← USPTO Patent Grants

Enhancing anti-tumor response in melanoma cells with defective sting signaling

Grant US12584919B2 Kind: B2 Mar 24, 2026

Assignee

H. Lee Moffitt Cancer Center

Inventors

James Mulé, Rana Falahat, Glen Barber

Abstract

Disclosed herein is a method for enhancing antitumor T cell responses in subjects. The method involves administering to the subject in need thereof a composition comprising a demethylating agent in an amount effective to demethylate STING proteins in the tumor cells. This method is particularly useful in subjects with deficient STING expression in the tumor cells. Therefore, also disclosed is a method for treating a tumor in a subject that involves detecting in a biopsy sample from the subject reduced STING expression, reduced cGAS expression, or a combination thereof; and then administering to the subject a demethylating agent in an amount effective to demethylate STING proteins in the tumor cells. The method can further involve administering to the subject a therapeutically effective amount of a STING agonist. The method can further involve administering to the subject tumor infiltrating lymphocytes (TILs), such as HLA-matched TILs.

CPC Classifications

G01N 33/5743 G01N 2800/52 A61K 35/17 C12N 5/0636 C12N 2501/01 C12N 2501/998 C12N 2502/30 C12N 2501/24

Filing Date

2022-09-16

Application No.

17932857

Claims

17